• Users Online: 213
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 38  |  Issue : 1  |  Page : 41-46

Cellular vascular endothelial growth factor and serum angiogenin in acute myeloid leukemia ( clinical and prognostic significance)

Department of Clinical Pathology, Hematology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Deena Samir Eissa
Department of Clinical Pathology, Ain Shams University Hospitals, Ramses St, Abbasia, 11566 Cairo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7123/01.EJH.0000423015.67835.8c

Rights and Permissions


Increased angiogenesis and angiogenic factors play an important role in hematologic malignancies. Acute myeloid leukemia (AML) is associated with a considerable increase in bone marrow vascularity. Vascular endothelial growth factor (VEGF) and angiogenin (ANG) are two prominent angiogenic mediators. Therefore, we aimed to examine the cellular expression of VEGF and serum ANG level in adult AML patients and to assess their prognostic impact on disease outcome.

Materials and methods

The study was carried out on 60 newly diagnosed adult AML patients compared with 25 age-matched and sex-matched controls. Patients were diagnosed and classified according to the French–American–British/WHO criteria by immunophenotyping and cytogenetic analysis. The cellular expression of VEGF in blast cells was assessed by flow cytometry. Serum levels of ANG were measured using a sandwich enzyme-linked immunosorbent assay.


AML blasts significantly overexpressed VEGF (median percentage expression, 30%; median mean fluorescence intensity, 3.8) compared with normal individuals (<5%; 0.57; P<0.01). Similarly, the serum levels of ANG were significantly higher in AML patients (mean±SD, 212.5±77.1 ng/ml) compared with the controls (mean±SD, 66±2.5 ng/ml; P<0.01). High levels of VEGF, above the median (>30%), together with serum ANG levels of AML patients showed no relationship with the studied clinical and laboratory parameters, French–American–British subtypes, or cytogenetic risk groups (P>0.05); however, they were significantly associated with a poor response to treatment and a higher mortality rate (P<0.01).


Cellular VEGF expression and serum ANG levels are significantly increased in AML patients and have been identified as independent poor prognostic indicators linked to accelerated angiogenesis and consequently a more aggressive disease outcome.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded405    
    Comments [Add]    

Recommend this journal